Navigation Links
Novartis Class Awarded $250 Million in Punitive Damages
Date:5/19/2010

NEW YORK, May 19 /PRNewswire/ -- After delivering a unanimous verdict against Novartis on all counts and awarding 12 former Novartis sales reps $3.36 million in compensatory damages yesterday, a New York jury today delivered a stronger dose of the same medicine.  Announcing the amount of punitive damages to be awarded, the jury determined that Novartis must pay an additional $250 million for the gender discrimination it inflicted on 5,600 working women in the class. The case was the largest gender discrimination matter ever to go to verdict in the U.S.

Monday's sweeping verdict found Novartis liable for gender discrimination in pay, promotional opportunities and pregnancy-related matters. Today's punitive damage award is meant to punish the company for its past actions and to deter it and others from continuing to discriminate against female employees in the future.

The announcement of punitive damages came after Judge McMahon instructed jurors to consider the amount of punitive damages award in light of the offensiveness of Novartis' behavior, the nature and extent of the harm done, the length of time the class endured the behavior, the extent to which Novartis knew about the discrimination and how they reacted once they were on notice and the amount needed to deter repetition of Novartis' conduct in light of Novartis' financial condition.

The women were represented in the matter by David Sanford, Steven Wittels and Katherine Kimpel in the New York and Washington, D.C. offices of Sanford, Wittels & Heisler LLP, and

SOURCE Sanford Wittels & Heisler LLP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
5. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
6. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
7. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
8. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
9. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
10. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
11. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  Tikcro Technologies Ltd. ... ended March 31, 2015. Aviv ... we continued pre-clinical work to generate functional specific antibodies, ... early stage, we are encouraged by the development progress. ... as new antibodies which modulate immune checkpoints gain clinical ...
(Date:5/27/2015)... Calif. , May 27, 2015  CytomX, ... treatment of cancer, today announced the appointments of ... and Cynthia Ladd as senior vice ... Goeltz was chief financial officer of Onyx Pharmaceuticals, ... an independent consultant and legal counsel to several ...
(Date:5/27/2015)... OAKS, Calif. , May 27, 2015  Ceres, ... has been awarded a U.S. patent for a genetic ... in areas such as research, product development and plant ... in regulating key biosynthetic processes that are the target ... offer other seed companies a commercial license to the ...
(Date:5/27/2015)... 2015 The Medical Innovation Impact Index ... regulation on medical innovation, has been developed at the ... Fairleigh Dickinson University’s ( FDU ) Rothman Institute of ... pertains to new FDA (Food & Drug Administration) draft ... approval of certain medical devices. , “The main ...
Breaking Biology Technology:Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2
... continue to have access to ZEVALIN(R) and other novel ... ... New Medicare legislation,passed by the House and Senate extends the ... and Medicaid,Services (CMS) had implemented new hospital outpatient reimbursement rates,for ...
... (Nasdaq: ALXA ) announced today that it has ... Directors. Dr. Barron is currently,Senior Vice President, Development and ... organization, which is responsible for,pre-clinical, clinical and post-approval activities., ... clinical scientist and was,promoted in 2002 to Vice President ...
... Amicus Therapeutics,Inc. (Nasdaq: FOLD ), ... chaperones for the treatment of human,genetic diseases, ... Phase 2 clinical trials of Amigal(TM) (migalastat ... Amigal is being developed in,partnership with Shire ...
Cached Biology Technology:House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 2House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 3Alexza Elects Dr. Hal V. Barron to Its Board of Directors 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 3Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 2Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 3Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 4Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 5Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 6
(Date:4/27/2015)... -- For more than four decades, AUVSI,s Unmanned Systems ... worldwide event for the unmanned land, sea, and air ... any local, national, or trade news organization interested in ... current applications of unmanned technologies. The conference will explore ... industry, and how it will soon impact the lives ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Tampa, Fla. (Mar. 12, 2009) A study to ... from a combination of autologous (patient self-donated) stem cell ... of ) oxygen treatment (HBO) before and after ASC ... glycemic control" along with "reduced insulin requirements." The combination ...
... a profound role in regulating global climate. But the ... have long struggled to accurately measure their composition, size, ... new satellite instrument developed by NASA scientists, the Aerosol ... Some types of small aerosols -- such as black ...
... software developed with help from the Wildlife Conservation Society ... by creating a three-dimensional model using photos taken by ... of the journal Biology Letters , may also ... The new software, developed by Conservation Research Ltd., creates ...
Cached Biology News:Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes 2New aerosol observing technique turns gray skies to blue 2New aerosol observing technique turns gray skies to blue 3New aerosol observing technique turns gray skies to blue 4Tracking tigers in 3-D 2
... is an optical unit that can be ... Dyad Disciple gradient-capable thermal cycler (purchased separately). ... shuttle that contains four LEDs for fluorescence ... 620-650 nm) and two filtered photodiodes for ...
... (LCM) is the method of choice for ... the only instrument to offer both LCM ... UV Laser Cutting provides unprecedented ... and capturing large numbers of cells. , ...
... highly sensitive laser confocal systems designed for ... scanners that meet your expectations, differentiating between ... optimizing the signal on the bottom as ... range for increased sensitivity. Results with VersArray ...
Hybridizer (220 V) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
Biology Products: